Boston Commerce (531458)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Book value per share of ₹9.20 provides a measurable asset base.
• Piotroski F-Score of 5/9 suggests some financial soundness, though not strong.
• 52-week price increase from ₹5.13 to ₹16.76 shows active trading interest and possible market catalyst.
• 80% profit growth indicates the loss may be narrowing, albeit from a negligible base.

Concerns

• Latest quarter sales are ₹0 crore, so there is no genuine revenue engine.
• Negative ROE of -6.61% and ROCE of -5.89% confirm shareholder value is being destroyed.
• P/E of 0.00 is meaningless without earnings, and the price is at the 52-week high of ₹16.76, offering poor risk-reward.
• Dividend yield is 0%, promoter holding is N/A, and debt/equity is N/A, leaving governance and capital structure opaque.

AI Analysis

At ₹16.76, Boston Commerce has a market capitalisation of just ₹4 crore. Benjamin Graham taught me to measure a business by its ability to generate earnings, not by price action. This company has no sales in the latest quarter — ₹0 crore — and net profit of ₹-0 crore. ROE is -6.61% and ROCE is -5.89%, so existing capital is being eroded. The quoted P/E of 0.00 is meaningless because there is no genuine profit; 80% profit growth is from an almost nonexistent base and therefore carries little weight. This is not an operating business in the usual sense; it is a shell with a healthcare services label trading at ₹16.76, well above book value of ₹9.20 per share. At 1.82 times book for a revenue-less, loss-making entity, there is no margin of safety. In fact, a Graham buyer would wait for a discount to net assets, not a premium. The 52-week range of ₹5.13 to ₹16.76 shows the stock has tripled, yet no fundamental earnings improvement has accompanied that move. The Piotroski F-Score of 5/9 suggests only moderate financial health. And with no dividend, no promoter holding data, and no debt-equity ratio, I cannot even complete a basic governance and leverage check. To invest here would be speculation based on chart movement and hope, not analysis. If the company later starts reporting real revenue, positive ROE, and a clear promoter stake, I will revisit. Until then, the rational approach is to stay away.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer